Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosapride vs domperidone plus twice-daily proton pump inhibitor for GERD in systemic sclerosis
TCTR20250609002Phase 3Recruiting
- Sponsor
- Thai Rheumatism Association
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mosapride, domperidone in gastroesophageal reflux disease (GERD), sponsored by Thai Rheumatism Association. Started May 2024; status: recruiting.
02
Drugs
mosapridedomperidone
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on TCTR20250609002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250609002.